BridgeBio Pharma Ownership
| 2CL Stock | EUR 65.04 0.48 0.73% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BridgeBio |
BridgeBio Stock Ownership Analysis
About 95.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 3.52. BridgeBio Pharma had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people. For more info on BridgeBio Pharma please contact Neil Kumar at 650 391 9740 or go to https://bridgebio.com.Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. For more detail on how to invest in BridgeBio Stock please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.